News & Updates

Precision medicine and tumour-agnostic approach are changing the landscape of non-small-cell lung cancer (NSCLC) and many other advanced solid tumours without satisfactory standard treatments. In an industry-sponsored meeting endorsed by the Hong Kong Society of Clinical Oncology, Professor Jürgen Wolf of the Center for Integrated Oncology, University of Cologne, Germany, lead investigator of an international phase II trial that led to the approval of capmatinib for advanced NSCLC harbouring MET exon 14 (METex14) skipping mutation, discussed the importance of panel molecular testing and targeted therapy in different solid tumours, focusing in particular on advanced NSCLC with actionable driver mutations, such as MET alterations.

Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.

Increased lipoprotein(a) (Lp[a]) appears predictive of long-term major adverse cardiovascular events (MACE) in people with and without baseline atherosclerotic cardiovascular disease (ASCVD), according to a recent study.

In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen^® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.